CHCWM – Cancer & Hematology Centers of West Michigan

GSK2857916 (DREAMM5) (GlaxoSmithKline Research)

GSK2857916 (DREAMM5)  (GlaxoSmithKline Research) 

Description:  As Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5

Mechanism of action:  anti BCMA antibody drug conjugate

Target Patient Population:  Multiple Myeloma

Study Design:  Study Drug is administered IV every 3 weeks.  Combination arms with Belantamab + other anti-myeloma agents